Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.54 |
| ▸ | ARG2 | P78540 | 4/20 | 0.48 |
| ▸ | ARG1 | P05089 | 3/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600685 | 1.00 | GSR (0.54) | GSRARG2ARG1GRIK1GRIK2 | |
| SCHEMBL2548396 | 1.00 | GSR (0.54) | GSRARG2ARG1GRIK1GRIK2 | |
| SCHEMBL2548695 | 0.94 | GSR (0.57) | GSRARG2ARG1GRIK1GRIK2 | |
| SCHEMBL2546200 | 0.94 | GSR (0.57) | GSRARG2ARG1GRIK1GRIK2 | |
| SCHEMBL2546202 | 0.94 | GSR (0.57) | GSRARG2ARG1GRIK1GRIK2 | |
| SCHEMBL2547202 | 0.92 | GSR (0.55) | GSRARG2ARG1GRIK1GRIK2 | |
| SCHEMBL2549431 | 0.92 | GSR (0.55) | GSRARG2ARG1GRIK1GRIK2 | |
| SCHEMBL2547204 | 0.92 | GSR (0.55) | GSRARG2ARG1GRIK1GRIK2 | |
| SCHEMBL2548392 | 0.86 | — | — | |
| SCHEMBL2550385 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637686-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2014-01-28 | — | — | US | claimed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | claimed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC (JP) | 2026-04-09 | — | — | US | disclosed |
| EP-4722228-A1 | NEW COMPOUND TARGETING MUSK AND USE THEREOF | The University of Tokyo (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | GENEFRONTIER CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250320471-A1 | Method for Producing Compounds, Method for Producing Compound Library, Compound Library, and Screening Method | UNIV TOKYO (JP) | 2025-10-16 | — | — | US | disclosed |
| EP-4594336-A2 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PeptiDream Inc. (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-4594337-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | Rayzebio, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-101663044-A | triazole macrocycle systems | AILERON THERAPEUTICS INC | 2010-03-03 | — | — | CN | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009149214-A2 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | AILERON THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-2114428-A2 | TRIAZOLE MACROCYCLE SYSTEMS | Aileron Therapeutics, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009126292-A2 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009099677-A2 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008104000-A2 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262200-A1 | Triazole Macrocycle Systems | FLT3, VIP, NGLY1 | GSR 3683/4885ARG2 219/4885ARG1 108/4885 |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | CXCL10, MLX, MICA | GSR 4749/4885ARG2 469/4885ARG1 61/4885 |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | GSR 4129/4885ARG2 791/4885ARG1 848/4885 |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | GSR 3683/4885ARG2 219/4885ARG1 108/4885 |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | EPHA2, EPHA1, EPHB1 | GSR 4580/4885ARG2 4640/4885ARG1 4144/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | GSR 4375/4885ARG2 474/4885ARG1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.